ARCHIVES

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

This article is from The Cancer Letter archive.

Vol. 18 No. 03 | January 17, 1992

Download PDF Visit The Full Archive

Related Articles

AACR Supports 5 Percent Increase in NCI Budget.

April 7, 2006

NCAB Asks Speedup Of OSP Coordinating Center Review

October 14, 1983

Aetna No Longer To Cover HDC/BMT For Breast Cancer Outside Of Clinical Trials.

February 25, 2000

FDA Policy: silicone Breast Implant Restrictions Stand, FDA Tells Petitioners

November 7, 1997

Program Announcement listed.

July 25, 2003

NIH Reauthorization Still Lingering, Bills ‘Tie Hands’ Of NCI Director

October 18, 1991